Post progression survival in glioblastoma: where are we? - sprookjes - yvandenbroek - TriplyDB

Post progression survival in glioblastoma: where are we?

Post progression survival in glioblastoma: where are we?

http://www.wikidata.org/entity/Q39103916

about

HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial.

P2860

Q40234446-28E03A6A-6AE1-4E0D-848E-ABF3BDFB9DD9

P2860

Post progression survival in glioblastoma: where are we?

http://www.wikidata.org/entity/Q39103916

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Post progression survival in glioblastoma: where are we?

@en

Post progression survival in glioblastoma: where are we?

@nl

type

label

Post progression survival in glioblastoma: where are we?

@en

Post progression survival in glioblastoma: where are we?

@nl

prefLabel

Post progression survival in glioblastoma: where are we?

@en

Post progression survival in glioblastoma: where are we?

@nl

P1433

Q39103916-8AAB52F9-50E9-45AE-8A3D-A200F6FAA821

P1476

Q39103916-CD2760F5-4900-4E58-BEFC-46F97174A549

P2093

Q39103916-1EF4F4E8-72FB-4B00-B4F3-BAC148E06915

Q39103916-765A429B-1072-4E87-B8F5-823DE45AC6E2

Q39103916-83B44641-816C-43A4-8219-3E9F33F77737

Q39103916-9C08379F-9A1C-48B0-8A3F-A06B9A72AB0F

Q39103916-A1D97015-2F33-4B53-A591-9E19EE7DC220

Q39103916-B463C8E8-6D27-47A4-914A-0EDD86AAA78A

Q39103916-B91E1405-E166-4EC5-BD26-622A1E538D45

Q39103916-BDC2BEC5-7E38-4E8E-839E-C5CDD1507956

Q39103916-CCA76FE8-90A6-4D6E-8B2F-4FBD49C26A7E

Q39103916-D187D247-7322-4EB4-9A8B-2FF70131C5B6

P2860

Q39103916-364FDC99-D7EB-4398-8397-4E05962F9669

Q39103916-42980294-7152-41D6-96E6-BB6F9CAD198F

Q39103916-43FF38CA-2239-4C4B-8EDB-BAB459BE1384

Q39103916-4F1538B8-E24E-4216-9947-C86DE79C0770

Q39103916-564C3EA8-3441-473D-ADE1-EBD2177D1D02

Q39103916-608D5CA9-9E4A-4AEB-A997-141BE7896D6B

Q39103916-66914064-222E-44B9-BB79-3A1CC21121BE

Q39103916-860C2634-7B8D-4C33-9610-C7E163F36B7A

Q39103916-8B840A0A-A81E-4076-AF18-4DF219D6809C

Q39103916-9E1EC792-6A80-42E0-A81B-5F0C94A6B43E

P2888

Q39103916-85E9A426-06B5-4134-A89B-89178ADC7AB4

P304

Q39103916-38A3025F-4605-4D95-B477-8184048F0B18

P31

Q39103916-4BD4E9E2-0CEB-483C-8326-B74DF07173CC

P356

Q39103916-7203AB8A-0707-477A-933A-CC96AD38D4C4

P433

Q39103916-C76CBE83-1F21-4A06-A7C2-13A0C4C458BF

P478

Q39103916-4287CAD0-2612-41A0-B699-EB99AAC53D85

P50

Q39103916-575CCCB2-9CC2-49A4-92AB-65F5705FA409

Q39103916-58DC8DFC-417E-4F41-A71A-CE60DB243DBE

Q39103916-C5F9285A-6474-4F32-BDAB-14501E42C65D

Q39103916-C89075F3-09F6-4147-AE1D-204C5554AD0D

Q39103916-DD3D3759-4563-42B8-A9B6-DC7E9BB3BFAC

P577

Q39103916-29EA4F9C-737D-4AE8-8FDE-67BE53E4F469

P698

Q39103916-5B7334B0-FD59-4834-A4DC-0F446D886807

P356

S11060-014-1651-7

P1433

Journal of Neuro-Oncology

P1476

Post progression survival in glioblastoma: where are we?

@en

P2093

Alba A Brandes

http://www.w3.org/2001/XMLSchema#string

Alicia Tosoni

http://www.w3.org/2001/XMLSchema#string

Antonella Bacci

http://www.w3.org/2001/XMLSchema#string

Antonio Fioravanti

http://www.w3.org/2001/XMLSchema#string

Claudio Ghimenton

http://www.w3.org/2001/XMLSchema#string

Eugenio Pozzati

http://www.w3.org/2001/XMLSchema#string

Girolamo Crisi

http://www.w3.org/2001/XMLSchema#string

Marco Bartolotti

http://www.w3.org/2001/XMLSchema#string

Mario Ermani

http://www.w3.org/2001/XMLSchema#string

Raffaele Agati

http://www.w3.org/2001/XMLSchema#string

P2860

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.

Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.

Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide.

The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme.

Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.

P2888

s11060-014-1651-7

P304

399-404

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11060-014-1651-7

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

121

http://www.w3.org/2001/XMLSchema#string

P50

Gianluca Marucci

Giovanni Tallini

Enrico Franceschi

Damiano Balestrini

P577

2014-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25366365

http://www.w3.org/2001/XMLSchema#string